Samsung Biologics Co.,Ltd is a contract development and manufacturing organization (CDMO) specializing in the biopharmaceutical sector. Its primary activities include cell line development, process development, and large-scale manufacturing of biologics, particularly monoclonal antibodies and antibody-drug conjugates (ADCs). The company claims to have significant production capabilities, with bioreactor facilities ranging from 1,000 to 15,000 liters. In 2023, Samsung Biologics Co.,Ltd reported a revenue of around $1.46 billion, serving mainly global pharmaceutical companies in the United States and Europe.
Headquarters
300 Songdo Bio Way (Daero), Yeonsu-Gu
Incheon; Incheon;
Contact Details: Purchase the Samsung Biologics Co., Ltd. report to view the information.
Website: http://www.samsungbiologics.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service